News and Announcements
Altech Chemicals SPP Closing Date 8 April
- Published April 06, 2016 11:53AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
6th April 2016, ASX Announcement
Altech Chemicals Limited (Altech/the Company) (ASX: ATC) reminds shareholders that the closing date for applications for additional shares under its current Share Purchase Plan (SPP) is 5pm (WST) Friday 8 April 2016. There will be no extension to the closing date.
The SPP enables existing shareholders of the Company with a registered address in Australia or New Zealand at the record date (18 March 2016) to apply for up to $15,000 of new fully paid ordinary shares in the Company at $0.086 per share, without incurring any brokerage or other transaction costs.
Personal entitlement forms for participation in the SPP were distributed to all eligible shareholders on 24 March 2016.
To view the full article please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
